Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

49.56 +1.23 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 832,093
Open 48.19
Bid (Size) 49.05 (1)
Ask (Size) 51.50 (1)
Prev. Close 48.33
Today's Range 48.14 - 50.29
52wk Range 30.46 - 59.75
Shares Outstanding 114,301,688
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire

Performance

YTD
+28.76%
+28.76%
1 Month
-6.67%
-6.67%
3 Month
-13.43%
-13.43%
6 Month
+27.73%
+27.73%
1 Year
+38.55%
+38.55%

More News

Read More
Analyst Expectations for Natera's Future
Via Benzinga
The Latest Analyst Ratings for Natera
Via Benzinga
Natera's Earnings Outlook
Via Benzinga
Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today
Via Investor's Business Daily
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Catalent Stock Showing Improved Relative Strength Rating
Via Investor's Business Daily
Natera Announces Commercial Payor Coverage for Signatera™
From Natera, Inc.
Via Business Wire
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
From Natera, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2023
Via Benzinga
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
From Natera, Inc.
Via Business Wire
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.